Xspray Pharma
Xspray Pharma: Shaping up to an exciting year (Redeye)
2019-03-19 07:30
In this update we look at the year ahead with the manufacturing and preparations to take HyNap-Dasa to market. We also update our view regarding the Sprycel, Nexavar and Tasigna market opportunities. We see a strong case in Xspray for the year going forward and reiterate our valuation range with a Base Case of SEK 135.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se